Contemporary protocols ensure high-remission rate and long-term free survival in children with acute lymphoblastic leukemia (ALL), but small percentage of patients is still incurable. Molecular genetic methods helped to establish submicroscopic classification as well as minimal residual disease follow-up, considered to be responsible for relapse. Our study enrolled 70 pediatric patients with de novo ALL, analyzed using reverse transcriptase-polymerase chain reaction for the presence of four major risk-stratifying translocations (BCR/ABL, MLL/AF4, TEL/AML1, and E2A/PBX1). Bone marrow samples were collected at diagnosis, at the end of induction phase, and after intensive chemotherapy with the aim to establish the correlation between chromosomal aberration, clinical features, and treatment response. Presenting the results of this study, we offer another evidence of variable incidence and clinical characteristics of ALL subtypes.
Pediatric acute lymphoblastic leukemia Fusion genes Clinical features Therapy response
This is a preview of subscription content, log in to check access.
This work was supported by Ministry of Science, Republic of Serbia (Grant No. 143051).
Wiemels JL, et al. Site-specific translocation and evidence of postnatal origin of the t(1;19) E2A-PBX1 fusion in childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA. 2002;99:15101–6. doi:10.1073/pnas.222481199.CrossRefPubMedGoogle Scholar
Van Dongen JJM, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: Investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13:1901–28. doi:10.1038/sj/leu/2401592.CrossRefPubMedGoogle Scholar
Schlieben S, et al. Incidence and clinical outcome of children with BCR/ABL positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALLBFM-90 and CoALL-05–92. Leukemia. 1996;10:957–63.PubMedGoogle Scholar
Iqbal Z, Iqbal M, Akhter T. Frequency of BCR/ABL fusion oncogene in Pakistani Childhood acute lymphoblastic leukemia (ALL). Patients reflect ethnic differences in molecular genetics of ALL. J Pediatr Hematol Oncol. 2007;29:585. doi:10.1097/MPH.0b013e3180f61bcf.CrossRefPubMedGoogle Scholar
Lo Nigro L, et al. Association of cytogenetic abnormalities with detection of BCR/ABL fusion transcripts in children with T-lineage lymphoproliferative diseases (T-ALL and T-NHL). Pediatr Blood Cancer. 2004;42:278–80. doi:10.1002/pbc.10453.CrossRefPubMedGoogle Scholar
Saglio G, et al. Consistent amounts of acute leukemia-associated P190BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis. Blood. 1996;87:1075–80.PubMedGoogle Scholar
Serrano J, et al. Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210 (BCR-ABL) and p190 (BCR-ABL) after alogenic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190 (BCR-ABL) detection precede cytogenetic relapse. Blood. 2000;95:2659–65.PubMedGoogle Scholar
Borkhardt A, et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Blood. 1997;90(2):571–7.PubMedGoogle Scholar
Shurtleff SA, et al. TEL/AML1 fusion resulting from a cryptic t(12;21) in the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia. 1995;9:1985–9.PubMedGoogle Scholar
Hunger SP, et al. E2A-PBX1 chimeric transcript status at end of consolidation in not predictive of treatment outcome in childhood acute lymphoblastic leukemias with t(1;19)(q23;p13), a Pediatric Oncology Group study. Blood. 1998;91:1021–8.PubMedGoogle Scholar
Mann G, Cazzaniga G, Van der Velden VHJ. Acute lymphoblastic leukemia with t(4;11) in children 1 year and older: The ‘big sister’ of the infant disease? Leukemia. 2007;21:642–6.PubMedGoogle Scholar